143 results
8-K
EX-99.4
KA
Kineta Inc
22 Dec 22
Kineta Completes Reverse Merger with Yumanity Therapeutics
5:02pm
are positioned to achieve multiple value-driving catalysts. We have assembled an experienced management team, a seasoned research and development team … rights in the form of licenses, promises to provide research and development services and promises to participate on certain development committees
8-K/A
EX-99.2
KA
Kineta Inc
3 Feb 21
Other Events
4:59pm
to conduct its research and development activities, the COVID-19 pandemic may cause disruptions that affect Yumanity’s ability to initiate and complete … preclinical studies and clinical trials or to procure items that are essential for Yumanity’s research and development activities. The pandemic has already
8-K/A
EX-99.7
KA
Kineta Inc
3 Feb 21
Other Events
4:59pm
to predict. While Yumanity continues to conduct its research and development activities, the COVID-19 pandemic may cause disruptions that affect … with the successful research, development and sales of marketed products for pipeline programs, as well as royalties on net sales. Yumanity will perform certain
8-K
EX-99.1
KA
Kineta Inc
24 Mar 22
Yumanity Therapeutics Reports Full-Year 2021 Financial Results and Recent Corporate Developments
4:21pm
requirements for a period of twelve months.
Research and development expense (R&D): Research and development expense was $26.4 million compared … loss of $50.8 million, or $21.57 per basic and diluted share for the prior year. The decrease was due to increased research and development expenses
8-K
EX-99.1
41y3 bdh7ws735hj
31 Mar 23
Kineta Reports Full Year 2022 Financial Results and Provides Corporate Update
4:03pm
8-K/A
EX-99.4
40dh8f1c
3 Feb 21
Other Events
4:59pm
8-K
EX-99.1
85jxv5l84pi7053jxh1p
31 Mar 21
Yumanity Therapeutics Reports Full Year 2020 Financial Results and Recent Corporate Developments
8:55am
8-K
EX-99.1
p6rak
11 Aug 23
Kineta Reports Second Quarter 2023 Financial Results and Provides Corporate Update
4:03pm
8-K/A
EX-99.1
ygmyiq
8 Apr 21
Financial Statements and Exhibits
8:42am
8-K
EX-99.2
wulg2grjhaj9
22 Dec 22
Kineta Completes Reverse Merger with Yumanity Therapeutics
5:02pm
10-K
gkvkn95 l5mi6zuoqx
30 Mar 16
Annual report
12:00am